Yuviwel Specialised Therapeutics Pharma Pty Ltd
Product name
Yuviwel
Accepted date
Jun-2026
Active ingredients
navepegritide
Summary of proposed indication
YUVIWEL (navepegritide) is proposed for the treatment of achondroplasia in children from birth. Achondroplasia is a genetic condition that affects bone growth and typically causes disproportionate short stature (average-sized torso but short limbs). YUVIWEL may be used while bones are growing, but not when bone growth plates (epiphyses) have closed, indicating no active bone growth.
Application type
A (new medicine)
Publication date
Jun-2026
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.